Altogether, our studies establish aberrant IL6 expression caused by Pax5 loss as a hallmark of Pax5-dependent B-ALL and the IL6 as a therapeutic vulnerability for B-ALL characterized by PAX5 loss. The gene discussed is PAX5; the disease is precursor B-cell acute lymphoblastic leukemia.